JP2013537400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537400A5 JP2013537400A5 JP2013513670A JP2013513670A JP2013537400A5 JP 2013537400 A5 JP2013537400 A5 JP 2013537400A5 JP 2013513670 A JP2013513670 A JP 2013513670A JP 2013513670 A JP2013513670 A JP 2013513670A JP 2013537400 A5 JP2013537400 A5 JP 2013537400A5
- Authority
- JP
- Japan
- Prior art keywords
- ala
- lys
- leu
- ser
- mutein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 28
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 25
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 21
- 102000003752 Lipocalin 1 Human genes 0.000 claims 18
- 108010057281 Lipocalin 1 Proteins 0.000 claims 18
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 14
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 9
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 6
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 5
- 101710017807 his-44 Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 101710017531 H4C15 Proteins 0.000 claims 2
- -1 His Chemical compound 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000036947 Dissociation constant Effects 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 1
- 125000003290 L-leucino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002041 N(2)-L-arginino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 230000002860 competitive Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 101700022040 his-42 Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Claims (16)
- ＩＬ−４レセプターαに対する結合親和性を有するヒト涙液リポカリンのムテインであって、
26の位置におけるPro, Leu, Asn, Tyr, Lys若しくはGlu；32の位置におけるLys；34の位置におけるTrp, Asn, Val, His若しくはArg；56の位置におけるLeu,Ala, His, Lys若しくはMet；58の位置におけるLeu；または、63の位置におけるLys,Ser, Gln若しくはProからなる群から選択される成熟ヒト涙リポカリンのアミノ酸ｐに対応する位置の少なくとも１つの置換を特徴とするヒト涙液リポカリンのムテイン。 - （i）成熟ヒト涙液リポカリンの直鎖状ポリペプチド配列の27, 28, 30, 31,33, 53, 57, 61, 64, 66, 80, 83, 104〜106及び108の配列位置の１つ又はそれ以上に変異されたアミノ酸残基を含み、
（ii）前記成熟ヒト涙液リポカリンの直鎖状ポリペプチド配列の26, 32, 34, 55,56, 58及び63の配列位置の２つ又はそれ以上に変異されたアミノ酸残基を含み、
前記ムテインのアミノ酸配列は、
(1)Ser 26, Glu34, Leu 55, Lys 58,
(2)Ser 26, Asn34, Ala 55, Lys 58,
(3)Ser 26, Val34,
(4)Pro 26, Ser34,
(5)Pro 26, Ala 55,
(6)Leu 26, Trp 34, Ala 55,
(7)Leu 26, Trp 34, Ile 58,
(8)Asn 26, Asp34,
(9)Asn 26, Ala55,
(10)Tyr 26, His 34, Ala 55,
(11)Tyr 26, His 34, Ala 58,
(12)Lys 26, Arg 34, Ala 55,
(13)Lys 26, Arg 34, Asn 58,
(14)Glu 26, Gly 34, Ala 55,
(15)Glu 26, Gly 34, Leu 58,
のアミノ酸の組み合わせのいずれか１つを含む請求項１に記載のヒト涙液リポカリンのムテイン。 - Ala 31, Tyr 33, Trp 61, Ser 80, Leu 104, Pro 106及びGln 108の少なくとも１つをさらに含む請求項１又は２に記載のヒト涙液リポカリンのムテイン。
- Phe 53, Leu 53, Tyr 64, Met 64, Leu 66及びAsp66の少なくとも１つをさらに含む請求項１又は２に記載のヒト涙液リポカリンのムテイン。
- Arg 27; Cys 28, Arg 30, Ala 31, Tyr 33, Arg 57, Trp 61, Ser 80, Arg83, Leu 104, Cys 105, Pro 106及びGln 108の少なくとも１つをさらに含む請求項１又は２に記載のヒト涙液リポカリンのムテイン。
- (1)Phe 53, Tyr 64, Leu 66と、
(2)Leu 53, Met 64, Asp 66と、
のうちの一方又は両方の群をさらに含む請求項１〜５に記載のヒト涙液リポカリンのムテイン。 - (1)Ser 26; Tyr 32; Leu 55; Gln 56; Lys 58;
(2)Pro 26; Tyr32; Ser 34; Ala 55; Gln 56; Lys 63;
(3)Leu 26; Phe32; Trp 34; Ala 55; Ile 58; Ser 63;
(4)Ser 26; Tyr32; Val 34; Ala 55; Ala 56; Ile 58; Ser 63;
(5)Ser 26; Val32; Asn 34; Ala 55; Gln 56; Lys 58; Lys 63;
(6)Asn 26; Lys 32; Asp 34; Ala 55; His 56; Arg 58; Gln 63;
(7)Tyr 26; Tyr 32; His 34; Ala 55; His 56; Ala 58; Lys 63;
(8)Lys 26; Tyr 32; Arg 34; Ala 55; Lys 56; Asn 58; Pro 63;及び
(9)Glu 26; His 32; Gly 34; Ala 55; Met 56; Leu 58; Lys 63
のいずれか１つの群を含む請求項１又は２に記載のヒト涙液リポカリンのムテイン。 - SEQ ID Nos:3-11のいずれか１つに示された請求項１又は２に記載のヒト涙液リポカリンのムテイン、又はそれらの断片若しくは変異体のヒト涙液リポカリンのムテイン。
- ＩＬ−４レセプターαに結合するヒト涙液リポカリンのムテインを生成する方法であって、
（i）成熟ヒト涙液リポカリンの直鎖状ポリペプチド配列の27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104〜106及び108のアミノ酸配列位置の１つ又はそれ以上と、
（ii）前記成熟ヒト涙液リポカリンの直鎖状ポリペプチド配列の26, 32, 34, 55,56, 58及び63のアミノ酸配列位置の２つ又はそれ以上とにおいて、
ヒト涙液リポカリンをコードする核酸分子に突然変異誘発させることにより、ヒト涙液リポカリンのムテインをコードする１つ又はそれ以上の核酸を得、
26の位置において突然変異された場合、突然変異体は、Ser, Pro, Leu,Asn, Tyr, Lys又はGluを含み；
32の位置において突然変異された場合、突然変異体は、Tyr, Val, Lys又はHisを含み；
34の位置において突然変異された場合、突然変異体は、Glu, Ser, Trp,Asn, Val, Asp, His, Arg又はGlyを含み；
55の位置において突然変異された場合、突然変異体は、Leu又はAlaを含み；
56の位置において突然変異された場合、突然変異体は、Gln, Leu, Ala,His, Lys又はMetを含み；
58の位置において突然変異された場合、突然変異体は、Lys, Ser, Ile,Arg, Ala, Asn又はLeuを含み；
63の位置において突然変異された場合、突然変異体は、Glu, Lys, Ser, Gln又はProを含むステップ（ａ）と、
（ａ）において得られた１つ又はそれ以上の前記ムテインの核酸分子を発現システムで発現することにより、１つ又はそれ以上のムテインを得るステップ（ｂ）と、
（ｂ）において得られた１つ又はそれ以上の前記ムテインを濃縮し、選択及び／又は単離により１０ｎＭ未満の解離定数でＩＬ−４レセプターαに結合するムテインを選択するステップ（ｃ）とを備えていることを特徴とする方法。 - 前記ステップ（ｃ）は、
ＩＬ−４レセプターα又はその免疫原性の断片を準備するステップ（ｃｉ）と、
１つ又はそれ以上の前記ムテインと前記ＩＬ−４レセプターα又はその免疫原性の断片とを接触させることにより、前記ＩＬ−４レセプターα又はその免疫原性の断片と結合親和力を有するムテインとの複合体を形成させるステップ（ｃｉｉ）とを含む請求項９に記載の方法。 - 前記ステップ（ｃ）の前記選択は、競合条件下で行われる請求項９又は１０に記載の方法。
- 前記ムテインは、
(1)Ser 26, Glu34, Leu 55, Lys 58,
(2)Ser 26, Asn34, Ala 55, Lys 58,
(3)Ser 26, Val34,
(4)Pro 26, Ser34,
(5)Pro 26, Ala 55,
(6)Leu 26, Trp 34, Ala 55,
(7)Leu 26, Trp 34, Ile 58,
(8)Asn 26, Asp34,
(9)Asn 26, Ala55,
(10)Tyr 26, His 34, Ala 55,
(11)Tyr 26, His 34, Ala 58,
(12)Lys 26, Arg 34, Ala 55,
(13)Lys 26, Arg 34, Asn 58,
(14)Glu 26, Gly 34, Ala 55,
(15)Glu 26, Gly 34, Leu 58
のアミノ酸の組み合わせのうちの１つを含む請求項９〜１１のいずれか１項に記載の方法。 - 請求項９〜１２のいずれか１項に従って取得可能である、又は、取得されることを特徴とするムテイン。
- 請求項１〜８および１３のいずれか１項に記載のムテインをコードするヌクレオチド配列を含むことを特徴とする核酸分子。
- 請求項１４に記載の核酸分子を含むことを特徴とする宿主細胞。
- 請求項１〜８及び１３のいずれか１項に記載のムテインを含むことを特徴とする医薬又は診断用の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35246110P | 2010-06-08 | 2010-06-08 | |
| US61/352,461 | 2010-06-08 | ||
| PCT/EP2011/059420 WO2011154420A2 (en) | 2010-06-08 | 2011-06-08 | Tear lipocalin muteins binding il-4 r alpha |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015218174A Division JP2016028604A (ja) | 2010-06-08 | 2015-11-06 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537400A JP2013537400A (ja) | 2013-10-03 |
| JP2013537400A5 true JP2013537400A5 (ja) | 2013-11-14 |
| JP5902679B2 JP5902679B2 (ja) | 2016-04-13 |
Family
ID=44627297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513670A Active JP5902679B2 (ja) | 2010-06-08 | 2011-06-08 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| JP2015218174A Pending JP2016028604A (ja) | 2010-06-08 | 2015-11-06 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| JP2019014631A Active JP6766194B2 (ja) | 2010-06-08 | 2019-01-30 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015218174A Pending JP2016028604A (ja) | 2010-06-08 | 2015-11-06 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| JP2019014631A Active JP6766194B2 (ja) | 2010-06-08 | 2019-01-30 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8986951B2 (ja) |
| EP (1) | EP2580236B1 (ja) |
| JP (3) | JP5902679B2 (ja) |
| CN (3) | CN105949301B (ja) |
| AU (1) | AU2011263786B2 (ja) |
| CA (1) | CA2800026C (ja) |
| CY (1) | CY1122339T1 (ja) |
| DK (1) | DK2580236T3 (ja) |
| ES (1) | ES2729652T3 (ja) |
| HR (1) | HRP20190689T1 (ja) |
| HU (1) | HUE043835T2 (ja) |
| LT (1) | LT2580236T (ja) |
| NZ (1) | NZ603562A (ja) |
| PL (1) | PL2580236T3 (ja) |
| PT (1) | PT2580236T (ja) |
| RS (1) | RS58839B1 (ja) |
| RU (1) | RU2569745C2 (ja) |
| SG (1) | SG186161A1 (ja) |
| SI (1) | SI2580236T1 (ja) |
| TR (1) | TR201906295T4 (ja) |
| WO (1) | WO2011154420A2 (ja) |
| ZA (1) | ZA201209160B (ja) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| RS58839B1 (sr) * | 2010-06-08 | 2019-07-31 | Pieris Pharmaceuticals Gmbh | Muteini lipokalina u suzama koji vezuju il-4 r alfa |
| MY178654A (en) | 2011-11-16 | 2020-10-20 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy |
| SG11201402351WA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
| ES2707878T3 (es) | 2011-11-16 | 2019-04-05 | Adrenomed Ag | Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para regular el equilibrio de líquidos en un paciente que presenta una enfermedad crónica o aguda |
| SI3553084T1 (sl) | 2011-11-16 | 2023-05-31 | Adrenomed Ag | Protitelo anti-adrenomedulina (ADM) ali fragment protitelesa anti-ADM ali anti-ADM non-IG ogrodje za preprečevanje ali zmanjšanje disfunkcije organa ali odpovedi organa pri pacientu s kronično ali akutno boleznijo ali akutnim stanjem |
| DK2594587T3 (da) | 2011-11-16 | 2014-07-21 | Adrenomed Ag | Anti-Adrenomedullin (ADM)-antistof eller anti-ADM-antistoffragment eller anti-ADM ikke-Ig-protein-scaffold til at reducere risikoen for mortalitet hos en patient med en kronisk eller akut sygdom eller akut tilstand |
| ES2751492T3 (es) | 2011-11-16 | 2020-03-31 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o armazón no Ig anti-ADM para uso en la terapia de una enfermedad aguda o una afección aguda de un paciente para estabilizar la circulación |
| HUE042720T2 (hu) | 2011-12-13 | 2019-07-29 | Pieris Pharmaceuticals Gmbh | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| WO2014053501A1 (en) | 2012-10-02 | 2014-04-10 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| WO2014076321A1 (en) * | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| WO2014108396A1 (en) | 2013-01-08 | 2014-07-17 | Sphingotec Gmbh | Fasting levels of growth hormone as a predictive marker of cardiovascular risk |
| JP6619650B2 (ja) * | 2013-03-14 | 2019-12-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 新規のｐｃｓｋ９結合タンパク質 |
| RU2673455C2 (ru) | 2013-03-20 | 2018-11-27 | Сфинготек Гмбх | Адреномедуллин для направленной терапии по снижению кровяного давления |
| EP3145945B1 (en) | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
| WO2016113203A1 (en) * | 2015-01-12 | 2016-07-21 | Pieris Ag | Engineered t cells and uses therefor |
| EP3286570A1 (en) | 2015-04-24 | 2018-02-28 | SphingoTec GmbH | A method for predicting the risk of incidence of chronic kidney disease |
| KR20180008649A (ko) | 2015-05-18 | 2018-01-24 | 피어이스 파마슈티컬즈 게엠베하 | 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| JP2019520550A (ja) | 2016-04-21 | 2019-07-18 | スフィンゴテック セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ３の定量方法および治療方法 |
| MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| SG11201900133WA (en) | 2016-07-08 | 2019-02-27 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| CN110167962A (zh) | 2016-12-16 | 2019-08-23 | 艾德里诺医药公司 | 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| CA3065415A1 (en) | 2017-05-30 | 2018-12-06 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| WO2019057992A2 (en) | 2017-09-25 | 2019-03-28 | Adrenomed Ag | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
| EP3698134A1 (en) | 2017-10-18 | 2020-08-26 | AdrenoMed AG | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| MX2020004219A (es) | 2017-10-24 | 2020-07-22 | Sphingotec Gmbh | Selenoproteina p para prediccion de un primer evento cardiovascular. |
| MX2020004271A (es) | 2017-10-25 | 2020-07-29 | 4TEEN4 Pharmaceuticals GmbH | Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. |
| BR112020014940A2 (pt) | 2018-02-08 | 2020-12-08 | Sphingotec Gmbh | Adrenomedulina (adm) para diagnóstico e/ou predição de demência e ligante antiadrenomedulina para uso em terapia e prevenção de demência |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| BR112021010069A2 (pt) | 2018-12-20 | 2021-11-23 | Sphingotec Gmbh | Selenoproteína p em insuficiência cardíaca |
| WO2020128039A2 (en) | 2018-12-21 | 2020-06-25 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| CN113613669A (zh) | 2019-03-29 | 2021-11-05 | 阿斯利康有限公司 | 用于治疗哮喘的脂质运载蛋白突变蛋白 |
| EP3946417A1 (en) | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| US20220291234A1 (en) | 2019-08-15 | 2022-09-15 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients |
| WO2021038078A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| US11231198B2 (en) | 2019-09-05 | 2022-01-25 | Trane International Inc. | Systems and methods for refrigerant leak detection in a climate control system |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CA3172349A1 (en) | 2020-02-27 | 2021-09-02 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| CN115244081A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂 |
| CN115244080A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| CN115769076A (zh) | 2020-03-16 | 2023-03-07 | 4Teen4制药有限公司 | 感染冠状病毒的患者中的dpp3 |
| WO2021185784A1 (en) | 2020-03-16 | 2021-09-23 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| PE20240799A1 (es) | 2020-12-18 | 2024-04-18 | Astrazeneca Ab | Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma |
| WO2022263648A1 (en) | 2021-06-18 | 2022-12-22 | Sphingotec Gmbh | A method for predicting sepsis and septic shock |
| WO2023275099A1 (en) | 2021-06-29 | 2023-01-05 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| CN113943374B (zh) * | 2021-09-24 | 2024-04-30 | 广东菲鹏制药股份有限公司 | 一种白介素15及其受体的多肽复合物 |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| SI1087778T1 (sl) | 1998-06-08 | 2006-02-28 | Hoffmann La Roche | Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2003099207A2 (en) | 2002-05-24 | 2003-12-04 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| AU2003275958A1 (en) * | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| RU2389796C2 (ru) * | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| US7404957B2 (en) | 2003-08-29 | 2008-07-29 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| WO2007107563A2 (en) | 2006-03-20 | 2007-09-27 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| DK2046820T3 (da) * | 2006-08-01 | 2011-02-07 | Pieris Ag | Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| AU2008274938A1 (en) | 2007-07-11 | 2009-01-15 | Aerovance, Inc. | Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation |
| RS58839B1 (sr) * | 2010-06-08 | 2019-07-31 | Pieris Pharmaceuticals Gmbh | Muteini lipokalina u suzama koji vezuju il-4 r alfa |
| HUE042720T2 (hu) * | 2011-12-13 | 2019-07-29 | Pieris Pharmaceuticals Gmbh | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
-
2011
- 2011-06-08 RS RS20190510A patent/RS58839B1/sr unknown
- 2011-06-08 NZ NZ603562A patent/NZ603562A/en unknown
- 2011-06-08 PL PL11726380T patent/PL2580236T3/pl unknown
- 2011-06-08 CN CN201610143597.4A patent/CN105949301B/zh active Active
- 2011-06-08 SI SI201131711T patent/SI2580236T1/sl unknown
- 2011-06-08 WO PCT/EP2011/059420 patent/WO2011154420A2/en active Application Filing
- 2011-06-08 ES ES11726380T patent/ES2729652T3/es active Active
- 2011-06-08 SG SG2012089116A patent/SG186161A1/en unknown
- 2011-06-08 TR TR2019/06295T patent/TR201906295T4/tr unknown
- 2011-06-08 CN CN201180028367.9A patent/CN103038249B/zh active Active
- 2011-06-08 EP EP11726380.6A patent/EP2580236B1/en active Active
- 2011-06-08 AU AU2011263786A patent/AU2011263786B2/en active Active
- 2011-06-08 PT PT11726380T patent/PT2580236T/pt unknown
- 2011-06-08 CA CA2800026A patent/CA2800026C/en active Active
- 2011-06-08 LT LTEP11726380.6T patent/LT2580236T/lt unknown
- 2011-06-08 DK DK11726380.6T patent/DK2580236T3/da active
- 2011-06-08 RU RU2012150766/15A patent/RU2569745C2/ru active
- 2011-06-08 HU HUE11726380A patent/HUE043835T2/hu unknown
- 2011-06-08 CN CN202010135181.4A patent/CN111499725A/zh active Pending
- 2011-06-08 JP JP2013513670A patent/JP5902679B2/ja active Active
- 2011-06-08 US US13/702,792 patent/US8986951B2/en active Active
-
2012
- 2012-12-05 ZA ZA2012/09160A patent/ZA201209160B/en unknown
-
2015
- 2015-03-23 US US14/665,692 patent/US9687524B2/en active Active
- 2015-11-06 JP JP2015218174A patent/JP2016028604A/ja active Pending
-
2017
- 2017-06-05 US US15/613,958 patent/US10232014B2/en active Active
-
2019
- 2019-01-24 US US16/256,331 patent/US10898545B2/en active Active
- 2019-01-30 JP JP2019014631A patent/JP6766194B2/ja active Active
- 2019-04-12 HR HRP20190689TT patent/HRP20190689T1/hr unknown
- 2019-06-06 CY CY20191100604T patent/CY1122339T1/el unknown
-
2020
- 2020-12-16 US US17/124,141 patent/US20210196788A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537400A5 (ja) | ||
| RU2012150766A (ru) | Мутеины липокалина слезы, связывающие альфа il-4 r | |
| Olsén et al. | Fibronectin binding mediated by a novel class of surface organelles on Escherichia coll | |
| RU2017135605A (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) | |
| JP2018526989A5 (ja) | ||
| RU2013108919A (ru) | Белки, связывающиеся с гепсидином | |
| KR20160130216A (ko) | 헤테로올리고머 미코박테리아 항원의 융합물 | |
| JP2017070289A5 (ja) | ||
| JP2016519051A5 (ja) | ||
| RU2015137158A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| RU2011153239A (ru) | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей | |
| JP2014521313A5 (ja) | ||
| IL256567A (en) | Rsv f polypeptides prior to stabilized soluble fusion | |
| JP2009539349A5 (ja) | ||
| JP2012525844A5 (ja) | ||
| JP2013517781A5 (ja) | ||
| RU2015142437A (ru) | Новые связывающие белки для pcsk9 | |
| CA2636075A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| JP2014506790A5 (ja) | ||
| JP2010529860A5 (ja) | ||
| JP2014523406A5 (ja) | ||
| JP2009511000A5 (ja) | ||
| KR20150016585A (ko) | 비-천연 컨센서스 알부민 결합 도메인 | |
| JP2013538566A5 (ja) | ||
| WO2016019726A1 (zh) | 低免疫原性抗TNF-α全人源单抗及其应用 |